Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Anti-Angiogenic Tyrosine Kinase Inhibitors for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Single-Arm Meta-Analysis.

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic tyrosine kinase inhibitors in 357 patients with recurrent or metastatic nasopharyngeal carcinoma. The pooled objective response rate was 48%, and the disease control rate was 83%, indicating promising antitumor activity, especially in immunotherapy-naive patients.

Key findings

• The pooled objective response rate (ORR) was 48% (95% CI: 39%-57%).
• The disease control rate (DCR) was 83% (95% CI: 77%-88%).
• The 1-year overall survival rate was 79% (95% CI: 68%-86%).
• The incidence of grade ≥ 3 treatment-related adverse events was 47% (95% CI: 37%-58%).

Why it matters

The findings suggest that combining PD-1/PD-L1 inhibitors with anti-angiogenic agents may enhance treatment options for patients with recurrent or metastatic nasopharyngeal carcinoma, particularly those who have not previously received immunotherapy.